Review of current and emerging therapies in type 2 diabetes mellitus.

Abstract

Significant advances in the treatment of type 2 diabetes mellitus (T2DM) include the implementation of prevention efforts aimed at delaying progression of glucose intolerance to overt diabetes mellitus (DM) and the development of new classes of blood glucose-lowering medications to supplement existing therapies. While the current management approach for T2DM continues to encompass traditional drugs that focus on β-cell failure and/or insulin resistance, newer agents that target other defects (eg, incretin deficiency/resistance) are increasingly incorporated. Furthermore, the effect of therapies on associated comorbidities (eg, dyslipidemia, hypertension, obesity, hypercoagulability) has become an additional therapeutic focus. This article provides a discussion of specific pharmacologic agents, based on guidelines from the American Diabetes Association/European Association for the Study of Diabetes and relevant clinical studies. An extensive update on the newest drugs (eg, incretin-based therapies, amylin agonists) and managed care aspects of diabetes care is also included.

• Authors: Nissa Mazzola
• Journal: The American journal of managed care (Am J Manag Care) Vol. 18 Issue 1 Suppl Pg. S17-26 (Jan 2012) ISSN: 1936-2692 [Electronic] United States
• PMID: 22559854 (Publication Type: Journal Article, Review)

Chemical References

• Blood Glucose
• Glycated Hemoglobin A
• Hypoglycemic Agents
• Insulin
• Sulfonylurea Compounds
• Thiazolidinediones

Topics

• Blood Glucose (metabolism)
• Diabetes Mellitus, Type 2 (drug therapy, epidemiology, prevention & control)
• Disease Progression
• Glycated Hemoglobin (analysis)
• Humans
• Hypoglycemic Agents (therapeutic use)
• Insulin (therapeutic use)
• Sulfonylurea Compounds (therapeutic use)
• Thiazolidinediones (therapeutic use)
• United States (epidemiology)